Brought to you by 
Otsuka gets exclusive rights to oncolytic virus therapy from Takara Bio; License Agreement Terminated
09 Nov 2021
Executive Summary
Otsuka Pharmaceutical Co. Ltd. licensed exclusive Japanese rights to develop and sell Takara Bio Inc.’s oncolytic virus therapy as a potential cancer treatment.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Otsuka gets exclusive rights to oncolytic virus therapy from Takara Bio; License Agreement Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice